Abstract

Introduction: Novel drugs have been shown to prolong life in men with metastatic prostate cancer (PCa) and castration resistant Pca (CRPC). The aim of Patient-overview Prostate cancer (PPC) is to register and report these treatments and their effect.

Material and methods: In PPC, a new part of the National Prostate Cancer Register of Sweden data on start and stop of treatments, imaging, prostate specific antigen, clinical assessment of progression and patient reported outcome measures (PROM) are registered from initiation of hormonal treatment. Data are displayed in a graph to inform clinical decisions for individual patients. For research, data in PPC are linked to PCBaSe with information from NPCR and a number of health care registers.

Results: In December 2019, 7 882 men had been registered in PPC out of whom 3 912 had reached the CRPC state. Median time to start of androgen receptor targeted drugs (ART) from start of ADT was 4 years (interquartile range IQR 6) for men with primary ADT, and 9 years (IQR 6) and for men with secondary ADT. Out of all men in PCBaSe with a prescription for ART in 2016-2017, PPC captured 1 480/4 055 (36%). There were small differences between men registered/not registered in PPC for cancer characteristics, primary treatment, comorbidity, and time on ADT before start of ART.

Conclusion: In PPC, use and effects of novel therapies for advanced Pca are assessed in a real-life setting. PPC data are used as a decision aid, for quality assurance, and in research.

摘要

简介：新药已显示可延长转移性前列腺癌（PCa）和去势抵抗性Pca（CRPC）男性的寿命。患者概述前列腺癌（PPC）的目的是注册并报告这些治疗方法及其效果。

材料和方法：在PPC中，瑞典国家前列腺癌登记系统中有关治疗开始和停止，影像学，前列腺特异性抗原，进展的临床评估以及患者报告的结局指标（PROM）的新数据已注册。治疗。数据显示在图表中，以告知个别患者的临床决策。为了进行研究，将PPC中的数据与NPCR和许多医疗保健登记簿中的信息链接到PCBaSe。

结果： 2019年12月，在PPC中注册了7882名男性，其中3912名达到了CRPC状态。从开始ADT开始到开始雄激素受体靶向药物（ART）的中位时间为原发性ADT的男性为4年（四分位间距IQR 6），而原发性ADT的男性为9年（IQR 6）。在2016-2017年所有接受过抗逆转录病毒治疗的PCBaSe男性中，PPC捕获了1 480/4 055（36％）。在开始接受抗逆转录病毒治疗之前，在PPC中注册/未注册的男性在癌症特征，主要治疗，合并症和ADT时间上存在微小差异。

结论：在PPC中，在现实生活中评估了晚期Pca的新疗法的使用和效果。PPC数据用作质量保证和研究的决策辅助。